Cellebrite Loses Nearly 30% While Omeros and CorMedix Add Nearly a Quarter of Their Value in a Single Session

by Carter Whitfield · August 13, 2026

Equities Reporter, The SmallCap Signal

The Russell 2000 finished Thursday at a record 3,052.85, a gain of 0.24%. Beneath that quarter-point move, second-quarter reporting produced a spread of more than 50 percentage points between the biggest small-cap winner and the biggest loser among the names below. The heaviest damage went to Cellebrite DI (Nasdaq: CLBT), the Israeli digital-forensics software company, which The Motley Fool's market wrap reported closed at $10.80, down 29.18%, or $4.45. Volume reached 36.6 million shares, which the site put at roughly 1,355% above the stock's three-month average, and the close sat close to the bottom of a 52-week range the Fool listed as $9.58 to $19.98.

The quarter was mixed; the outlook was the problem. Israeli technology outlet Calcalist reported Cellebrite posted second-quarter revenue of $131.1 million, up 16% year over year, annual recurring revenue of $507.8 million, up 21%, and adjusted EBITDA of $31.8 million for a 24.2% margin. On a GAAP basis, though, net income fell to $6.4 million, or $0.02 a share, from $19.5 million, or $0.08, a year earlier, and non-GAAP income slipped to $29.7 million from $30.8 million, according to RTTNews's summary of the release. The real damage came from the reset to the year. Calcalist reported the company lowered its 2026 ARR outlook to $550 million to $560 million and cut full-year revenue guidance to $555 million to $561 million from a prior $565 million to $571 million, while raising its adjusted EBITDA target to $153 million to $159 million from $149 million to $155 million. That is a reshaping rather than a straight cut — less revenue, more margin — but the market treated the revenue line as the one that mattered. The reductions were attributed to longer sales cycles and weaker-than-expected expansion from customer conversions to the company's Inseyets platform. The report also came with a leadership change: Shiven Ramji, who joined Cellebrite in May 2026 as president of products and technology, has replaced Thomas Hogan as chief executive. Ramji said the company was taking a more measured view of newer-product contribution in the near term given elongated sales cycles, while adding that tangible progress on those products supported its confidence in the long-term opportunity.

At the other end of the tape, two small-cap drug developers were rewarded for the swing to profitability that the sector spends years promising. Omeros (Nasdaq: OMER), which put out its numbers after Wednesday's close, finished Thursday up 24.07% at $17.01, according to Stock Analysis price data. The company's quarterly filing shows why: net income of $13.2 million in the second quarter, reversing a $25.4 million loss a year earlier, with diluted earnings of $0.15 a share and basic earnings of $0.18. The driver was YARTEMLEA, approved by the FDA in December 2025 and launched in January, which generated $28.5 million of product sales in the quarter against nothing in the prior-year period, and $38.4 million through June 30. Omeros ended the half with $2.0 million in cash and equivalents plus $130.0 million in short-term investments, and still carries $54.8 million of 2029 convertible notes after July repurchases along with a $157.9 million OMIDRIA royalty obligation — leverage that remains material against a company with 72.1 million shares outstanding.

CorMedix (Nasdaq: CRMD), which reported before Thursday's opening bell, rose 23.45% to close at $8.77. Its release, distributed via BioSpace, put consolidated second-quarter revenue at $101.9 million and net income at $26.0 million, or $0.33 basic and $0.29 diluted per share, with DefenCath contributing $66.1 million. The company held $256.7 million in cash and short-term investments excluding restricted cash. Notably, CorMedix maintained rather than raised its full-year revenue guidance of $325 million to $345 million while lifting its adjusted EBITDA range to $125 million to $140 million and narrowing cash operating expense guidance to $145 million to $155 million — a margin story rather than a top-line one, as the company works through the post-TDAPA reimbursement environment for its catheter lock solution.

Home-health provider Aveanna Healthcare (Nasdaq: AVAH) was the session's best small-cap earnings reaction of those surveyed here, closing up 24.75% at $11.29 after reporting before the open. It posted second-quarter revenue of $670.5 million, up 13.7% year over year, and net income of $40.3 million against $27.0 million a year earlier. Adjusted EBITDA rose 8.0% to $95.4 million. The company raised full-year 2026 guidance to revenue above $2.68 billion, from a prior $2.63 billion to $2.65 billion range, and adjusted EBITDA above $365 million, from $338 million to $342 million. Chief Executive Jeff Shaner said in the release that the second quarter results demonstrate the momentum across Aveanna and the company's ability to consistently deliver sustained year-over-year growth. The balance sheet remains leveraged: the release listed total indebtedness of $1.48 billion against $97.2 million of cash, with $85.3 million of operating cash flow generated in the first six months.

Consumer names participated too. Wolverine World Wide (NYSE: WWW) was up about 11% by mid-morning, according to Investrade's mid-morning market look, after reporting second-quarter revenue of $506.4 million, up 6.8% and 6.1% in constant currency, with adjusted diluted earnings of $0.40 a share. Merrell revenue grew 11.1% to $175.5 million and Saucony 9.9% to $158.6 million. The company raised full-year revenue guidance to $1.980 billion to $2.000 billion from $1.960 billion to $1.985 billion, and adjusted diluted EPS to $1.55 to $1.65 from $1.43 to $1.58. President and Chief Executive Chris Hufnagel said the team delivered another good quarter, ahead of the company's expectations — led again by Merrell and Saucony — along with more progress in Sweaty Betty and Wolverine.

The losing column extended well past Cellebrite, and pre-market quotes proved a poor guide to where these names actually finished. Benzinga's pre-market decliners list had tokenization firm Securitize (NYSE: SECZ) down 19.8% at $6.30 on worse-than-expected results; it closed at $5.70, down 27.48%. The same list showed Alpha & Omega Semiconductor (Nasdaq: AOSL) off 11.6% at $32.09 after its fiscal fourth-quarter report, and Investrade still had it down only about 8% at mid-morning, attributing the disappointment in part to Typhoon Dolphin disruptions in China, seasonality and memory constraints in PCs — but the stock finished at $30.62, down 15.60%. Specialty insurer Pelagos Insurance Capital (NYSE: PLGO), which released results after Wednesday's close, was quoted down 10% at $21.90 pre-market and ended the day down 8.88% at $22.16. Chip-adjacent and newly listed financial-technology names remain among the thinnest-traded corners of the small-cap universe, where a single disappointing quarter can move a stock 20% before a market maker has quoted a second print.

StubHub Holdings (NYSE: STUB) offered the session's clearest illustration that beating on revenue is no longer sufficient. The ticket marketplace, which reported after Wednesday's close, disclosed second-quarter revenue of $573.1 million, up 33%, gross merchandise sales of $3.1 billion, up 34%, net income of $14.6 million against a $53.8 million loss a year earlier, and adjusted EBITDA of $105.7 million, up 94%. Free cash flow was $309.7 million. Chief Executive Eric Baker said in the release that the second quarter demonstrated strong demand for live events, highlighted by a record-setting World Cup. The stock fell anyway, closing Thursday at $7.68, down 10.07%, after Benzinga's pre-market decliners list had it off 18% at $7.00 and TheStreet's live blog put the pre-market drop at 20.42%. Two things bothered the market. The first was the per-share line: despite the reported net income, basic and diluted earnings per share came in at $(0.00), against analyst estimates that had been comfortably positive. The second was arithmetic: StubHub raised its full-year GMS outlook to $10.1 billion to $10.3 billion but merely reiterated adjusted EBITDA guidance of $400 million to $420 million, implying the record quarter does not translate into a higher full-year profit number.

The pattern across Thursday's reactions — to reports filed either before the open or after Wednesday's close — is consistent enough to be useful. Companies that raised full-year guidance — Aveanna, Wolverine — were bought. Companies that beat on the quarter but left the year unchanged, or lifted one line while cutting another, were sold, sometimes violently. Cellebrite raised its EBITDA target and still lost nearly a third of its equity value because it cut the recurring-revenue line that investors use to model the business. CorMedix did something structurally similar and rose 23.45%, the difference being that it left revenue guidance intact rather than cutting it.

With the second-quarter calendar not yet exhausted, the read-through for the rest of the season is that the burden of proof has shifted to the outlook rather than the print. That matters disproportionately in small caps, where reporting-day liquidity is thin, index-level records provide no cushion to individual names, and a 25% single-session move in either direction is now an ordinary outcome rather than an exceptional one.